Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031070 · ClinicalTrials.gov registry record · Phase 2
Increasing HAART-Induced Immune Restoration With Cyclosporine
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00031070: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00031070 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 40 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031070, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood. This study also will explore the safety of briefly giving cyclosporine to patients starting HAART.
Interventions
- DRUG Cyclosporine
- DRUG Efavirenz
- DRUG Abacavir sulfate, Lamivudine and Zidovudine
- BIOLOGICAL Pneumococcal Conjugate Vaccine, Heptavalent
- BIOLOGICAL Hepatitis A Vaccine (Inactivated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00031070 record still lists
NCT00031070 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclosporine is the first listed.
NCT00031070 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00031070 about?
NCT00031070 is a clinical study titled "Increasing HAART-Induced Immune Restoration With Cyclosporine". The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood. This study also will explore the safety of briefly giving cyclosporine to patien...
What is the current status of trial NCT00031070?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00031070?
The interventions under investigation include: Cyclosporine (DRUG), Efavirenz (DRUG), Abacavir sulfate, Lamivudine and Zidovudine (DRUG), Pneumococcal Conjugate Vaccine, Heptavalent (BIOLOGICAL), Hepatitis A Vaccine (Inactivated) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00031070?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00031070's enrollment target sits among peer trials
40 1362nd of 2000 higher than 542 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models